Celmatix Names Dr. Erin Foran Wolff as Chief Medical Officer

Experienced Medical Professional to Support Company During
Important Period of Growth

May 18, 2016 09:00 AM Eastern Daylight Time

NEW YORK--(EON: Enhanced Online News)--Celmatix,
a personalized medicine company focused on fertility and women’s health,
today announced it has named Dr. Erin Foran Wolff as its first Chief
Medical Officer. In this position, Dr. Wolff will play an important role
as the company prepares to launch its first genetic test and continues
to scale its analytics platform, Polaris, already in use at leading
fertility clinics across the US. In addition, Dr. Wolff will help
support the ongoing clinical research efforts of the company.

“This position gives me the unique opportunity to do both by developing
better tools to provide care for women more effectively.”

Dr. Wolff comes to Celmatix from the National Institutes of Health in
Washington, D.C., where she conducted basic, translational, and clinical
reproductive research as an Assistant Clinical Investigator for the past
five years. Dr. Wolff received her M.D. from Washington University
School of Medicine in St. Louis, Missouri. After completing her
residency training in Obstetrics and Gynecology at Yale-New Haven
Hospital in New Haven, Connecticut, she became a Scholar of the
Reproductive Scientist Development Program at Yale University School of
Medicine. She then completed a fellowship in Reproductive Endocrinology
and Infertility at the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (NICHD).

“Dr. Wolff joins us at a key point in the growth of Celmatix,” explained
Dr. Piraye Yurttas Beim, Celmatix Founder and CEO. “We are continuing to
scale our clinical data network and product offerings through our
Polaris platform and also accelerate our research and development
pipeline. Dr. Wolff’s deep experience and expertise as an OB/GYN,
reproductive endocrinology and infertility specialist, and NIH clinical
investigator, will be a major asset to Celmatix.”

Dr. Wolff commented, “I’ve always felt a strong commitment to both
patient care and research. My work at Celmatix will allow me to continue
to move the needle in patient care, while also contributing to the
ground-breaking research for which the company is known.” She continued,
“This position gives me the unique opportunity to do both by developing
better tools to provide care for women more effectively.”

About CelmatixCelmatix is a personalized medicine company
that uses big data and predictive analytics to help individuals who are
struggling to have a baby make informed decisions. Founded in 2009 and
based in New York City, Celmatix is disrupting the way women approach
their lifelong fertility journey by empowering them through science and
technology. The company’s flagship product, Polaris, is in use at top
fertility clinics across the country and is the world’s first analytics
platform for optimizing fertility. Celmatix also has an active research
and development program dedicated to decoding the genetic basis of
fertility potential. For more information, visit www.celmatix.com.